Kohjin BioKohjin Bio Co., Ltd.177A東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP
About 51% of Kohjin Bio's sales come from Microbiological business, with Tissue culture business and Cell process business making up much of the rest.
Out of every ¥100 of sales, about ¥27 is left as operating profit.
For every ¥100 Kohjin Bio sells, how much goes where, and how much is kept.
Margin funnel (derived from reported values)Gross margin 51.7% → Operating margin 26.7% → Net margin 17.5%
Revenue by business segment, and the profit each one keeps.
※ Segment figures include inter-segment sales and do not sum to the company total
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.